TECHNETIUM TC 99M MERTIATIDE KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M MERTIATIDE KIT (TECHNETIUM TC 99M MERTIATIDE KIT).
Technetium Tc 99m mertiatide is a radiopharmaceutical diagnostic agent that undergoes renal tubular secretion and glomerular filtration, allowing for dynamic imaging of renal function and urinary tract patency.
| Metabolism | Not metabolized; excreted unchanged primarily by the kidneys via glomerular filtration and tubular secretion. |
| Excretion | Renal: approximately 50% excreted unchanged in urine within 2 hours; 70% within 24 hours. Biliary/fecal: negligible. |
| Half-life | Terminal elimination half-life: approximately 1.5–2 hours for the non-protein-bound fraction; allows rapid imaging within 30 minutes and clearance from blood pool. |
| Protein binding | Approximately 50% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution: approximately 0.3 L/kg (range 0.2–0.4 L/kg), reflecting distribution into extracellular fluid and renal tissue. |
| Bioavailability | Not applicable (administered only intravenously); bioavailability 100% by IV route. |
| Onset of Action | Intravenous injection: visualization of renal parenchyma within 1–2 minutes; peak renal activity at 3–5 minutes. |
| Duration of Action | Duration of diagnostic imaging: 30–45 minutes post-injection for dynamic renography; effective imaging up to 1 hour. Continued renal excretion clears tracer over 24 hours. |
1-10 mCi (37-370 MBq) intravenously as a single dose for renal imaging.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required; however, image quality may be affected in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | No dose adjustment needed; not hepatically metabolized. |
| Pediatric use | 0.05-0.15 mCi/kg (1.85-5.55 MBq/kg) intravenously, minimum 0.3 mCi (11.1 MBq). |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M MERTIATIDE KIT (TECHNETIUM TC 99M MERTIATIDE KIT).
| Breastfeeding | Technetium Tc 99m mertiatide is excreted in breast milk. The M/P ratio is not established. Breastfeeding should be interrupted for at least 24-48 hours after administration to minimize infant radiation exposure. Pump and discard milk during this period. |
| Teratogenic Risk | Technetium Tc 99m mertiatide is a radiopharmaceutical. In pregnancy, radiation exposure to the fetus is a concern. First trimester: highest risk for teratogenesis; use only if benefit outweighs risk. Second and third trimesters: lower risk, but cumulative radiation dose should be minimized. No specific teratogenic effects reported; however, theoretical risk of fetal harm exists due to radiation. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to any component of the kit.","Not indicated for use in patients with known or suspected pregnancy unless benefit clearly outweighs risk."]
| Precautions | ["Risk of allergic reactions including anaphylaxis.","Use caution in patients with severe renal impairment due to reduced clearance.","Pregnancy: Consider risk vs benefit; radiation exposure to fetus.","Lactation: Interrupt breastfeeding for 24 hours post-dose."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during administration. No specific fetal monitoring required; however, ensure proper hydration to promote renal clearance and reduce radiation burden. Confirm pregnancy status before administration. |
| Fertility Effects | No known effects on fertility. Radiation exposure to gonads could theoretically affect fertility, but at diagnostic doses, such effects are unlikely. |